On September 6, 2019 DiaMedica Therapeutics Inc. (Nasdaq: DMAC) reported that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth (BIG3) Conference on Thursday, September 12th, 2019, at the Parker New York in New York City (Press release, DiaMedica, SEP 6, 2019, View Source [SID1234539347]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DiaMedica’s President and Chief Executive Officer, Rick Pauls, is scheduled to meet with investors on Thursday, September 12th, with one-on-one meetings to be held throughout the day.

About the BIG3 Conference
Lake Street will host its third annual B.I.G. (Best Ideas Growth) institutional investor conference at the Parker New York, showcasing many interesting, dynamic public growth companies. Executives from approximately 65 publicly traded companies will meet institutional investors in an interactive, one-on-one meeting format. This is an invitation-only event attended by top institutional investors from across the country.

For more information, visit View Source or contact your Lake Street representative or email [email protected].

On September 6, 2019 Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, reported that Stanley C. Erck, President and Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference (Press release, Novavax, SEP 6, 2019, View Source [SID1234539346]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Date and Time: Tuesday, September 10, 11:15 a.m. – 11:40 a.m. E.T.
Location: Holmes II, Lotte New York Palace Hotel, New York
Live webcast: www.novavax.com, "Investors"/"Events"
A replay of the presentation will also be accessible under the "Investors/Events" section www.novavax.com.

On September 6, 2019 Omeros Corporation (Nasdaq: OMER), reported that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York next week. The presentation is scheduled for Tuesday, September 10, 2019 at 10:00 a.m. EDT (Press release, Omeros, SEP 6, 2019, View Source [SID1234539345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast. The live and archived webcasts can be accessed on the investor relations section of the company’s website at www.omeros.com under "Events."

On September 6, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported that Daniel J. O’Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the 21st Annual H.C. Wainwright Global Investment Conference on Monday, September 9, 2019, at 10:25 a.m. Eastern Time in New York, NY (Press release, OncoSec Medical, SEP 6, 2019, View Sourcenews/detail/2006/oncosec-to-present-at-the-21st-annual-h-c-wainwright-global-investment-conference [SID1234539343]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Investors section of OncoSec’s website at View Source, where it will be archived for approximately 30 days.

On September 6, 2019 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the "Company") reported that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will present a corporate overview at the 21st Annual H.C. Wainwright Global Investment Conference on Monday, September 9, 2019 at 12:30pm ET in New York, NY (Press release, Aurinia Pharmaceuticals, SEP 6, 2019, https://ir.auriniapharma.com/news/detail/154/aurinia-pharmaceuticals-to-present-at-the-21st-annual-h-c-wainwright-global-investment-conference [SID1234539342]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of the presentation will also be archived on the Company website for thirty days following the event.